Differences in the intracellular fate of free and polymer-bound doxorubicin

Journal of Controlled Release

Volumn 80, Issue 1-3, 2002, Pages 101-117

  Hovorka, Ondřej ^a   St'astny M ^a   Etrych, T ^b   Subr V ^b   Strohalm, J ^b   Ulbrich, K ^b   Ihova, B ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Apoptosis; Doxorubicin; HPMA copolymer; Intracellular transport; Necrosis

Indexed keywords

DOXORUBICIN; DRUG CARRIER; MONOCLONAL ANTIBODY; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYMER; PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTERNALIZATION; INTRACELLULAR TRANSPORT; LASER MICROSCOPY; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GENES, P53; HUMANS; INTRACELLULAR MEMBRANES; MICE; POLYMERS; TUMOR CELLS, CULTURED;

EID: 0037161313     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00016-0     Document Type: Article

References (46)

1. Targetable polymeric anticancer drugs. Temporal control of drug activity
2. Drug-polymer conjugates: Potential for improved chemotherapy
3. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
4. Antibody-targeted polymer-bound drugs
5. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs
6. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens
7. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier
8. 2-targeted conjugates and combined therapy with immunomodulators
9. Immunoprotective therapy with targeted anticancer drugs
10. Biological properties of targetable poly N-(2-hydroxypropyl)methacrylamide-antibody conjugates
11. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action
12. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and antitumor agent SMANCS
13. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
14. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting
15. Comparison of effects of doxorubicin and radiation on p53-dependent apoptosis in vivo
16. p53-dependent DNA damage-induced apoptosis requires Fas/Apo-1-independent activation of Cpp32beta
17. Apoptosis of human tumor cells by chemotherapeutic anthracyclines is enhanced by Bax overexpression
18. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells
19. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin
20. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells
21. Visualization of the effect of the targeted drugs
22. Differences in cytotoxic effect of free and polymer bound doxorubicin
23. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors
24. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma
25. Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells
26. Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling
27. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation
28. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B
29. Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide
30. A phase I clinical trial of PK1: A novel drug targeting system in human cancers
31. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
32. Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody
33. Establishment and characterization of permanent murine hybridomas secreting monoclonal anti-Thy-1 antibodies
34. Detection of apoptosis at the single-cell level by direct incorporation of fluorescein-dUTP in DNA strand breaks
35. Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes
36. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells
37. p53-mediated apoptosis: Mechanisms and regulation
38. Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity
39. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats
40. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate
41. Interaction of cationic N-(2-hydroxypropyl)methacrylamide copolymer with rat liver in vivo
42. Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates
43. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat
44. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro
45. Phase I clinical trial of HPMA copolymers bearing doxorubicin and galactosamine
46. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine